Cryptogenic cerebral venous thrombosis in a multiple-sclerosis-patient treated with Alemtuzumab.

Abstract

Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis (MS). Its molecular target is CD 52, a GPI-anchored protein. Herein, we describe the case of a 40-year-old man with MS treated with alemtuzumab, who developed cerebral sinus thrombosis. In the literature, alemtuzumab was associated with venous thrombosis, attributed to a paroxysmal nocturnal hemoglobinuria (PNH)-like mechanism. In our case, no PNH clones were detected. Other common causes of cerebral venous thrombosis, like infections and thrombophilia, were excluded, thus the pathogenic mechanism remains obscure.

• Authors: Sara Gasparini, Margherita Russo, Vincenzo Dattola, Edoardo Ferlazzo, Umberto Aguglia
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 44 Pg. 102246 (Sep 2020) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 32540745 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Chemical References

• Alemtuzumab

Topics

• Adult
• Alemtuzumab (adverse effects)
• Hemoglobinuria, Paroxysmal
• Humans
• Male
• Sclerosis
• Venous Thrombosis (diagnostic imaging)